Spero Therapeutics, Inc. · NASDAQ:SPRO
Spero Therapeutics — Investor Presentation (August 2025)
19 slides from Spero Therapeutics's investor presentation, Aug 12, 2025
Slide 1: Corporate Presentation August 2025
Corporate Presentation August 2025 Exhibit 99.2
Slide 2: Forward-looking Statement
Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, statements regarding, among other things, the potential number of patients who could be treated by tebipenem H
Slide 3: Developing Therapies for Rare and Multi-drug Resistant Infectious Diseases
Clinical stage portfolio Strong financial foundation Tebipenem HBr in Phase 3 for cUTI Indications with high unmet need in addressable patient populations Orphan drug and/or QIDP designations Strong global intellectual property Developing Therapies for Rare and Multi-drug Resistant Infectious Diseas
Slide 4: Maturing Pipeline with Differentiated Clinical Assets
Asset Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestone Partnered Assets Tebipenem HBr cUTI Phase 3 complete; US regulatory submission expected in 2H 20251 Wholly Owned SPR720 First-line NTM-PD Complete data analysis & determine next steps2 Maturing Pipeline with Differentiated Cl
Slide 5: Tebipenem HBr Oral Carbapenem for cUTI
Tebipenem HBr Oral Carbapenem for cUTI
Slide 6: Complicated Urinary Tract Infection (cUTI)
Complicated Urinary Tract Infection (cUTI) cUTIs are associated with an abnormality of the urinary tract or in the presence of catheterization Patients with pyelonephritis1, regardless of underlying abnormalities of the urinary tract, are considered a subset of cUTI patients cUTIs are more likely ca
Slide 7: Overview of cUTI Therapeutic Landscape
Overview of cUTI Therapeutic Landscape IV: intravenous; tebipenem HBr: tebipenem pivoxil hydrobromide (formerly SPR994); UTI: urinary tract infection 1. Carreno JJ, et al. Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infect
Slide 8: Tebipenem HBr: Positioned to Change the Treatment Landscape for cUTI Patients
Tebipenem HBr: Positioned to Change the Treatment Landscape for cUTI Patients Potential first-to-market oral carbapenem Phase 3 stopped for efficacy Global commercial partnership Orally bioavailable carbapenem prodrug that rapidly converts to active moiety tebipenem Potential use as an effective or
Slide 9: PIVOT-PO: Pivotal Phase 3 Clinical Trial Design
Phase 3 Clinical Trial PIVOT-PO: Pivotal Design 1. supported by confirmatory evidence from PK/PD and breakpoint package AP: acute pyelonephritis; cUTI: complicated urinary tract infection; NI: non-inferiority; TBP-PI-HBr/tebipenem HBr: tebipenem pivoxil hydrobromide (formerly SPR994) Study Tebipenem
Slide 10: Compound Structures and Definitions
Compound Structures and Definitions TBP-PI-HBr is an orally bioavailable carbapenem prodrug that rapidly converts in enterocytes to active moiety tebipenem Tebipenem has in vitro activity against multidrug-resistant (MDR) Gram-negative pathogens, including extended-spectrum ß-lactamase (ESBL)-produc
Slide 11: Clinical Experience Supports Tebipenem HBr Safety and Efficacy
741 Adult subjects evaluated, across 17 efficacy and pharmacology trials 440 pediatric subjects evaluated, across 6 efficacy and pharmacology trials Generally well tolerated, comparable to common, approved oral beta lactam antibiotics and IV carbapenems Met its primary endpoint in 3 double blind con
Slide 12: Activity of Tebipenem and Comparator Carbapenems against Uropathogens
Activity of Tebipenem and Comparator Carbapenems against Gram-negative and -positive Uropathogens Pathogen N MIC90 (µg/mL) Pathogen N Tebipenem Imipenem Meropenem Ertapenem Enterobacterales (Surveillance US & EU, 2022) E. coli 1,444 0.03 ≤0.12 0.03 0.015 K. pneumoniae 404 0.12 0.5 0.06 0.25 P. mirab
Slide 13: Tebipenem Active Against Resistant Enterobacterales UTI Pathogens
Tebipenem is Active Against Clinically Important Resistant Enterobacterales UTI Pathogens from Europe and the USA in 2022 * Spero data on file. ESBL = Extended spectrum beta-lactamases; TMP-SMX = Trimethoprim-Sulfoxazole; R = Resistant; NS= Non susceptible; CRE = Carbapenem Resistant Enterobacterale
Slide 14: Tebipenem Pharmacokinetic Profile
Tebipenem Pharmacokinetic Profile Prodrug rapidly converts to tebipenem in enterocytes of GI tract Plasma Half-life ~1 hour Dose-proportional PK relationship when administered fed or fasted state Low potential for drug-drug interactions No CYP450-dependent metabolism No induction of CYP450 enzymes E
Slide 15: Tebi Well Positioned As First Oral Carbapenem for cUTI
Tebi Well Positioned As First Oral Carbanepenem for cUTI Company Product Pharmacological Class Development Stage Spero Tebipenem HBr BL (Carbapenem) Phase 3 – stopped for efficacy VenatoRx Ceftibuten-ledaborbactam etzadroxil BL/BLI Phase 1 Shionogi/Qpex Ceftibuten-xeruborbactam oral prodrug BL/BLI P
Slide 16: Exclusive License Agreement with GSK for Tebipenem HBr and Equity Investment
Exclusive License Agreement with GSK for Tebipenem HBr and Equity Investment FPFD: first patient first dose. SPA: Special Protocol Assessment. 1. Under the terms of the GSK License Agreement, the milestone amount was revised from $150M after PIVOT-PO was stopped early for efficacy following completi
Slide 17: SPR720 Antibiotic for NTM-PD
The company has suspended its current development for SPR720 SPR720 Antibiotic for Non-Tuberculosis Mycobacterium Pulmonary Disease (NTM-PD)
Slide 18: SPR720: Inhibits Gyrase B in Bacterial Cells
SPR720: Inhibits Gyrase B in Bacterial Cells Novel mechanism of action for NTM-PD not exploited by current antibiotics No evidence of cross resistance against marketed antibiotics based on in vitro trials Low propensity for development of resistance as monotherapy and in combination with SOC antibio
Slide 19: Thank You
SPERG THERAPEUTICS Thank You
Spero Therapeutics — Investor Presentation (August 2025) on 6ix